Bibliography
- FUJISHIGE K, KOTERA J, MICHIBATA H et al.: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. (1999) 274:18438-18445.
- LOUGHNEY K, SNYDER PB, UHER L, ROSMAN GJ, FERGUSON K, FLORIO VA: Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene (1999) 234:109-117.
- SODERLING SH, BAYUGA SJ, BEAVO JA: Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl Acad. Sci. USA (1999) 96:7071-7076.
- FUJISHIGE K, KOTERA J, OMORI K: Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur. J. Biochem. (1999) 266:1118-1127.
- COSKRAN TM, MORTON D, MENNITI FS et al.: Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J. Histochem Cytochem. (2006) 54:1205-1213.
- SEEGER TF, BARTLETT B, COSKRAN TM et al.: Immunohistochemical localization of PDE10A in the rat brain. Brain Res. (2003) 985:113-126.
- KOTERA J, SASAKI T, KOBAYASHI T, FUJISHIGE K, YAMASHITA Y, OMORI K: Subcellular localization of cyclic nucleotide phosphodiesterase type 10A. J. Biol. Chem. (2004) 279:4366-4375.
- XU RX, HASSELL AM, VANDERWALL D et al.: Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (2000) 288:1822-1825.
- CARD GL, ENGLAND BP, SUZUKI Y et al.: Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (2004) 12:2233-2247.
- MANALLACK DT, HUGHES RA, THOMPSON PE: The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J. Med. Chem. (2005) 48:3449-3462.
- SUNG BJ, YEON HK, HO JY et al.: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature (2003) 425:98-102.
- FUJISHIGE K, KOTERA J, YUASA K et al.: The human phosphodiesterase PDE10A gene. Eur. J. Biochem. (2000) 267:5943-5951.
- KOTERA J, FUJISHIGE K, YUASA K et al.: Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem. Biophys. Res. Commun. (1999) 261:551-557.
- GROSS-LANGENHOFF M, HOFBAUER K, WEBER J et al.: cAMP is a ligand for the tandem gaf domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J. Biol. Chem. (2006) 281:2841-2846.
- XIE Z, ADAMOWICZ WO, ELDRED WD et al.: Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience (2006) 139:597-607.
- SIUCIAK JA, CHAPIN DS, HARMS JF, LEBEL LA, McCARTHY SA, CHAMBERS L: Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology (2006) 51:386-396.
- SIUCIAK JA, McCARTHY SA, CHAPIN DS et al.: Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology (2006) 51:374-385.
- RODEFER JS, MURPHY ER, BAXTER MG: PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neuroscience (2005) 21:1070-1076.
- HUANG Z, LIU S, ZHANG L et al.: Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci. (2006) 78:2663-2668.
- GIBSON LCD, HASTINGS SF, MCPHEE I et al.: The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur. J. Pharmacol. (2006) 538:39-42.
- MENNITI FS, FARACI WS, SCHMIDT CJ: Phosphodiesterases in the CNS: targets for drug development Nat. Drug Disc. Rev. (2006) 5:660-670.
Patents
- ICOS CORPORATION: WO1999042596 (1999).
- NOVANEURON, INC.: WO2001024781 (2001).
- BAYER PHARMACEUTICALS CORPORATION: WO2002048144 (2002).
- PFIZER PRODUCTS, INC.: EP1250923 (2002).
- ASTA-WERKE: DE 614703 (1932).
- PFIZER PRODUCTS, INC.: US2003018047 (2003).
- PFIZER PRODUCTS, INC.: WO2003093499 (2003).
- PFIZER PRODUCTS, INC.: EP1281771 (2003).
- PFIZER PRODUCTS, INC.: EP1321034 (2003).
- PFIZER PRODUCTS, INC.: US2005182079 (2005).
- PFIZER PRODUCTS, INC.: WO2005082883 (2005).
- PFIZER PRODUCTS, INC.: US2005202550 (2005).
- PFIZER PRODUCTS, INC.: WO2005120514 (2005).
- BAYER PHARMACEUTICALS CORPORATION: WO2005012485 (2005).
- PFIZER PRODUCTS, INC.: US2006019975 (2006).
- PFIZER PRODUCTS, INC.: US4370328 (1983).
- PFIZER PRODUCTS, INC.: WO2006070284 (2006).
- PFIZER PRODUCTS, INC.: WO2006072828 (2006).
- BAYER PHARMACEUTICALS CORPORATION: WO2003000269 (2003).
- BAYER PHARMACEUTICALS CORPORATION: WO2003014117 (2003).
- BAYER PHARMACEUTICALS CORPORATION: WO2003014116 (2003)
- BAYER PHARMACEUTICALS CORPORATION: WO2003014115 (2003).
- BAYER PHARMACEUTICALS CORPORATION: WO2003051877 (2003).
- ALTANA PHARMA AG: WO2005002579 (2005).
- ALTANA PHARMA AG: WO2005003129 (2005).
- ALTANA PHARMA AG: WO2006089815 (2006).
- ALTANA PHARMA AG: WO2005003130 (2005).
- MEMORY PHAMACEUTICALS CORP.: WO2006028957 (2006).
- MEMORY PHAMACEUTICALS CORP.: WO2006071988 (2006).
- KYORIN PHARMACEUTICAL CO. LTD: DE2315801 (1973).
- KYORIN PHARMACEUTICAL CO. LTD: WO2004050091 (2004).
- KYOWA HAKKO KOGYO CO. LTD: WO2004002484 (2004).